Considering the informationregarding α and β selectivityand its correlation with lipogenesis, we were able to design agoniststhat show strongly improved selectivity for LXRα and demonstratestrong therapeutic efficacy in combination with a DFG-out Raf inhibitorin HCC cells and liver cancer organoid cultures. This evidence concerns the gene NR1H3 and hepatocellular carcinoma.